Alphamab Oncology Presented the Dose-escalation Results from JSKN003 in Patients with Advanced/Metastatic Solid Tumors at AACR
- Written by PR Newswire
- The dose-escalation results of JSKN003 was reported at this AACR conference.
- JSKN003 exhibited a favorable tolerability, safety profile and encouraging preliminary antitumor activity in patients with HER2-expressing advanced/metastatic solid tumors. The ORR in patients with HER2+ BC was 100%. No DLT was observed, MTD has not been reached yet.
SU...